BNET Industries
Market Cap:$147.2B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Can Roche Leave Genentech Alone?
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer Inc. and Wyeth; Analysis of Agreement Containing Consent Order To Aid Public Comment and...
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
-
EDITORIAL: Difficult mix of business, science
-
$75M verdict unsealed in Prempro-cancer case
-
Sanofi-Aventis on hunt for Boston partners
-
Pfizer says in partnership deal with BMP in China
-
Pfizer Inc. PFE Says in Partnership Deal with BMP Sunstone in China
-
Still Enjoying Those Acquisitions, Pfizer?
-
Status Of Pfizer And Wyeth Research Facilities
-
Monsanto MON Agrees to Acquire Pfizer's PFE Chesterfield Village Research Center for $435M
News & Analysis
Filter by
biotech and pfizer inc. - All News and Analysis
Pfizer Increases R&D Commitment in China
Seeking Alpha
- 2009-11-26
ChinaBio Today submits: Pfizer (NYSE: PFE) will expand its China R&D operations by adding facilities in central and western China, according to a Reuters story. The company will build a new clinical R&D center in Wuhan, which will support global clinical drug programs, including Phase I-IV clinical trials. Pfizer...
Pfizer's People Aren't to Blame
Seeking Alpha
- 2009-10-22
Derek Lowe submits: I wanted to highlight a comment that showed up recently in the latest Pfizer PFE post: I would just like to point out that there is often mention of Pfizer as being a poorly productive R&D outfit on this blog, but there is...
Auxilium Inches Toward FDA Approval for Xiaflex
Seeking Alpha
- 2009-10-14
Zacks.com submits: Auxilium Pharma AUXL is currently awaiting a decision from the U.S. Food and Drug Administration (FDA) on its key pipeline candidate, Xiaflex, which is under FDA review for the treatment of Dupuytren’s Contracture. In September, Auxilium received a major boost in the form of a favorable...
Which Pfizer / Wyeth Sites Will Shut Down?
Seeking Alpha
- 2009-09-28
Derek Lowe submits: I have no solid information on this question myself, but Eric Milgram over at Pharmaconduct is trying a wisdom-of-crowds approach. He's got a survey up of which sites people think will close, and it'll be interesting to see how well this matches up with the eventual...
Big Pharma's Future Death Spiral?
Seeking Alpha
- 2009-09-18
Derek Lowe submits: One of this blog's regular correspondents has just been attending a chemistry outsourcing conference program here, and heard a very interesting talk from Stefan Loren of a Baltimore investment advisory firm, Westwicke Partners. Loren's a product of the Sharpless lab, who went on to Abbott ABT,...
Pfizer Whistle-Blowing: The How and Why
Seeking Alpha
- 2009-09-06
Derek Lowe submits: Here's more detail on the case that led to Pfizer's PFE 2.3 billion dollar fine/settlement, courtesy of Bloomberg. Here's how things got started, apparently: Pfizer Inc. sales folks had one tough customer in psychiatrist Stefan Kruszewski. He didn’t buy their pitch to prescribe...
Justice Department Makes 2.3 Billion Dollar Example of Pfizer's Marketing Practices
Seeking Alpha
- 2009-09-03
Derek Lowe submits: No sooner do I write another post about pharma marketing than Pfizer PFE finds itself paying 3.2 billion dollars in fines for doing it improperly. 1.2 billion of that is a criminal penalty, and needless to say, they've set the current record. The...
FDA Calendar Updates: Medivation, Pfizer, AstraZeneca
Seeking Alpha
- 2009-07-30
Mike Havrilla submits: Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 288 entries as of 7/30/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA....
Pfizer Underwrites Basic Research at Shanghai Institutes
Seeking Alpha
- 2009-07-30
ChinaBio Today submits: Pfizer (NYSE: PFE) has teamed up with the Shanghai Institutes for Biological Sciences (SIBS) to do basic research. The biggest of pharmas will underwrite $500,000 of health-related basic research projects at SIBS for each of the next three years. Pfizer and SIBS will select the research...
Pfizer's Compound Screen Doesn't Look Like a Great Moneymaker
Seeking Alpha
- 2009-05-20
Derek Lowe submits: I've heard that Pfizer PFE is doing something unusual with its proprietary compound collection: they're offering to let other people screen it. Now, that's quite a step. Most companies guard their compounds pretty closely, considering them to be key assets. But I'm told...
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
